http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2012036214-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2011-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2012036214-A1 |
| titleOfInvention | Therapeutic and preventive drugs for autoimmune diseases, inflammatory diseases, allergic diseases, and symptoms associated with organ transplantation |
| abstract | The present invention is selected from the group consisting of novel autoimmune diseases, inflammatory diseases, allergic diseases and symptoms associated with organ transplantation, which can artificially control the activity of the IL-6 amplifier and control the immune response of the living body The main objective is to provide a therapeutic or prophylactic agent for at least one disease or condition. Furthermore, another object of the present invention is to provide an immunosuppressive agent, an inflammatory cytokine production inhibitor, and an IL-6 amplifier inhibitor. Compounds that can suppress the functional expression of proteins belonging to the ErbB1 pathway provided as a means to solve such problems can suppress the activity of IL-6 amplifier and reduce the production of inflammatory cytokines such as IL-6 Can be made. Therefore, a compound capable of inhibiting the function of a protein belonging to the ErbB1 pathway is a treatment of at least one disease or symptom selected from the group consisting of autoimmune diseases, inflammatory diseases, allergic diseases and symptoms associated with organ transplantation. It can be used as an active ingredient of drugs or prophylactic drugs. |
| priorityDate | 2010-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 354.